The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation

Abstract Multiple myeloma (MM) remains an incurable disease in need of the development of novel therapeutic agents and drug combinations. ABT‐199 is a specific Bcl‐2 inhibitor in clinical trials for MM; however, its activity as a single agent was limited to myeloma patients with the t(11;14) translo...

Full description

Bibliographic Details
Main Authors: Pasupathi Sundaramoorthy, Cristina Gasparetto, Yubin Kang
Format: Article
Language:English
Published: Wiley 2018-07-01
Series:Cancer Medicine
Subjects:
Bcl‐2 inhibitor
multiple myeloma
SK2 inhibitor
sphingosine kinase 2
Online Access:https://doi.org/10.1002/cam4.1543

Similar Items

Similar Items